Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?

Talking Euretina
30/04/2025 36 min Temporada 2 Episodio 61
Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?

Listen "Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Sarah Mrejen (France), Associate Professor Salomon Cohen (France), and Associate Professor Dinah Zur (Israel) explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.

More episodes of the podcast Talking Euretina

Episode 72: Bridging the Gap - Why Diversity in Retina Trials Can’t Wait 27/11/2025
Episode 71: Restoring Vision with Bionics: Inside the Prima Implant Breakthrough 10/11/2025
Episode 70: Highlights from the Euretina Congress 2025 in Paris. 19/09/2025
Episode 69: Pioneering Retina: Prof. Ursula Schmidt-Erfurth on AI, AMD & 25 Years of Euretina 31/08/2025
Episode 68: AI, Epidemiology & Innovation: Prof. Korobelnik on the Future of Retina 28/08/2025
Episode 67: Throwing Away Wisdom – Maria Berrocal on Saving Proven Treatments for PDR and Retinal Detachment 15/08/2025
Episode 66: A Holistic Approach? Patient Experience, Mental Health and Emotional Intelligence 01/08/2025
Episode 65: Decoding White Spot Syndromes: Multimodal Imaging, Challenges & Clinical Clarity 15/07/2025
Episode 64: New Frontiers in Submacular Hemorrhage: Insights from Ophthalmologica 01/07/2025
Episode 63: Beyond Borders: Navigating Ophthalmology Fellowships Abroad 17/06/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA